Brief: BiomX Announces Dosing Of First Subject In Phase 2 Study Of BX001
March 2 (Reuters) - Biomx Inc PHGE.A :
* BIOMX ANNOUNCES DOSING OF FIRST SUBJECT IN PHASE 2 STUDY
OF
BX001 FOR ACNE-PRONE SKIN
* BIOMX INC - INTERIM DATA READOUT EXPECTED IN Q3 OF 2021
Source text for Eikon: ID:nBw1rpqKda
Further company coverage: PHGE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tessera Defense and Homeland Security
See all newsBrief: Tessera Defense & Homeland Security - Enters $5 Million Revolving Credit Agreement With Mandragola On Oct 5, 2026 - SEC Filing
Brief: Biomx - Announces One-For-Ten Reverse Stock Split Of Common Stock - SEC Filing
Brief: Biomx And Water.Io Agree To Updated Zorronet Acquisition Terms
Brief: BiomX - May Offer And Sell Up To $9.10 Million Of Common Stock Through Wainwright - SEC Filing
Brief: Biomx Provides Update On Defense Technology Portfolio And Growth Strategy